BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 9134632)

  • 1. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended treatment for venous thromboembolism: how long is long enough?
    Cosmi B; Palareti G
    Curr Hematol Rep; 2004 Sep; 3(5):375-81. PubMed ID: 15341706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
    Simioni P; Prandoni P; Lensing AW; Scudeller A; Sardella C; Prins MH; Villalta S; Dazzi F; Girolami A
    N Engl J Med; 1997 Feb; 336(6):399-403. PubMed ID: 9010145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
    Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
    Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.
    Kyrle PA; Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Melichart M; Traxler G; Weltermann A; Speiser W; Lechner K
    Thromb Haemost; 1997 May; 77(5):829-33. PubMed ID: 9184387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women.
    Tormene D; Simioni P; Prandoni P; Luni S; Zerbinati P; Sartor D; Franz F; Girolami A
    Haematologica; 2001 Dec; 86(12):1305-9. PubMed ID: 11726323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overweight, obesity, and the risk of recurrent venous thromboembolism.
    Eichinger S; Hron G; Bialonczyk C; Hirschl M; Minar E; Wagner O; Heinze G; Kyrle PA
    Arch Intern Med; 2008 Aug; 168(15):1678-83. PubMed ID: 18695082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII.
    Eischer L; Gartner V; Schulman S; Kyrle PA; Eichinger S;
    Ann Hematol; 2009 May; 88(5):485-90. PubMed ID: 18931845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene.
    Eichinger S; Minar E; Hirschl M; Bialonczyk C; Stain M; Mannhalter C; Stümpflen A; Schneider B; Lechner K; Kyrle PA
    Thromb Haemost; 1999 Jan; 81(1):14-7. PubMed ID: 10348706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.
    Hoke M; Kyrle PA; Minar E; Bialonzcyk C; Hirschl M; Schneider B; Kollars M; Weltermann A; Eichinger S
    Thromb Haemost; 2005 Oct; 94(4):787-90. PubMed ID: 16270631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K; Eriksson H; Lundström T; Billing Clason S; Wall U; Nyström P; Wessman P; Schulman S;
    Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.